DOCSLIB.ORG

Product Information

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Product Information PRODUCT DATA DOUGLAS LABORATORIES® 03/2018 1 TestoQuench™ for Men Hormone Specific Formulation™ DESCRIPTION TestoQuench™ for Men is a Hormone Specific Formulation™ of herbal ingredients that to help moderate the actions of testosterone. This combination of herbs is designed to support the healthy function of the prostate and other testosterone-sensitive tissues in men. ‡ The Hormone Specific Formulation™ line of products, provided by Douglas Laboratories® and formulated by Dr. Joseph J Collins, was created to support the optimal function of specific hormones through the use of hormone specific adaptogens and modulators of hormone signaling. This formulation may be used as part of a hormone health program with dietary and nutrient support. In addition, these formulations may be used by clinicians as an adjuvant to support optimal hormone health in patients who have been prescribed bioidentical hormone therapies. ‡ FUNCTIONS TestoQuench™ for Men is a unique combination of phytochemicals designed to promote healthy hormone balance by supporting the ideal function of testosterone-sensitive tissues. These phyto-compounds moderate tissue sensitivity to androgens or the actions of these hormones in part through targeting 5-alpha-reductase, an enzyme that converts testosterone to the more androgenic dihydrotestosterone. Saw palmetto has been demonstrated to moderate 5-alpha-reductase, and may support the function of the urethra. Oral piperine supports higher plasma concentrations of a variety of glycoproteins inhibiting P-glycoprotein (P-gp) and CYP34A. Preliminary studies also show it may inhibit testosterone 5ɑ-reductase.‡ INDICATIONS • Support for prostate health and testosterone balance in men. ‡ FORMULA (#202410) Serving size………………………. 2 veg. caps……..4 veg. caps Proprietary Blend........................ 1,440 mg ……….2,880 mg Saw Palmetto berry Extract (Serenoa repens, standardized to 25% fatty acids), Magnolia officinalis bark Extract (standardized to 5% honokiol), Stinging Nettle leaf Extract (Urtica dioica, standardized to 1% silica), Holy Basil (Ocimum sanctum, leaf), Pygeum africanum (bark, standardized to 2.5% sterols) BioPerine® ……………………….10 mg ………… 20 mg (black pepper fruit extract/Piper nigrum) Other ingredients: Hydroxypropyl methylcellulose (capsule), silica, and hydroxypropyl cellulose. BioPerine® is a registered trademark of Sabinsa Corporation Non-GMO, Gluten Free SUGGESTED USE As a dietary supplement, adults take 2-4 capsules daily with food or as directed by a healthcare professional. INTERACTIONS Not to be taken by pregnant or lactating women. If you have any health condition or are taking any medication, consult your health professional before use. STORAGE Store in a cool, dry place, away from direct light. Keep out of reach of children. PRODUCT DATA DOUGLAS LABORATORIES® 03/2018 2 TestoQuench™ for Men Hormone Specific Formulation™ REFERENCES Gulcin I, Kufrevioglu OI, Oktay M, Buyukokuroglu ME. J Ethnopharmacol. 2004 Feb;90(2-3):205-15. [Urtica dioica L.] Kelm MA, Nair MG, Strasburg GM, DeWitt DL. Phytomedicine. 2000 Mar;7(1):7-13. [Ocimum sanctum Linn.]. Papaioannou M, et al. Invest New Drugs. 2010 Dec;28(6):729-43. [Pygeum africanum]. Prager N, Bickett K, French N, Marcovici G. J Altern Complement Med. 2002 Apr;8(2):143-52 Bharadwaj et al., JPET 302:645–650, 2002. [piperine] Gerber GS, Zagaja GP, Bales GT, Chodak GW, Contreras BA. Urology 1998;51(6):1003-1007. [saw palmetto] Saidi S, Stavridis S, Stankov O, Dohcev S, Panov S. Hyperplasia.Pril. 2017 Sep 1;38(2):123-129. [saw palmetto] Sinescu I, Geavlete P, Multescu R, Gangu C, Miclea F, Coman I, et al. Urol Int 86: 284–289 [saw palmetto] Hirata N, et al. Biol. Pharm. Bull. 30(12) 2402—2405 (2007). [piperine] For more information on TestoQuench™ visit douglaslabs.com Hormone Specific Formulation™ is a trademark of Your Hormones, Inc. ‡These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Manufactured by Douglas Laboratories 600 Boyce Road Pittsburgh, PA 15205 800-245-4440 2015 Douglas Laboratories. All Rights Reserved douglaslabs.com 202410-032018 .
Load more

Recommended publications
  • Highly Water-Soluble Solid Dispersions of Honokiol: Preparation, Solubility, and Bioavailability Studies and Anti-Tumor Activity Evaluation
    pharmaceutics Article Highly Water-Soluble Solid Dispersions of Honokiol: Preparation, Solubility, and Bioavailability Studies and Anti-Tumor Activity Evaluation Li Wang 1,2, Weiwei Wu 1,2, Lingling Wang 1,2, Lu Wang 1,2 and Xiuhua Zhao 1,2,* 1 College of Chemistry, Chemical Engineering and Resource Utilization, Northeast Forestry University, Harbin 150040, China; [email protected] (L.W.); [email protected] (W.W.); [email protected] (L.W.); [email protected] (L.W.) 2 Key Laboratory of Forest Plant Ecology, Northeast Forestry University, Ministry of Education, Harbin 150040, China * Correspondence: [email protected]; Tel.: +86-451-82191517; Fax: +86-451-82102082 Received: 18 September 2019; Accepted: 24 October 2019; Published: 1 November 2019 Abstract: Honokiol (HK), a well-tolerated natural product, has many multiple pharmacological activities. However, its poor water solubility and low bioavailability limit its clinical application and development. The aim of this research was to prepare the solid dispersion (SD) formulation of honokiol (HK) with poloxamer-188 (PLX) as the carrier, thereby improving its solubility and oral bioavailability. Firstly, by investigating the relationship between the addition amount of the PLX and the solubility of HK, and the effects of solid dispersions with different ratios of HK–PLX on the solubility of HK, we determined that the optimum ratio of PLX to HK was (1:4). Then, the HK–PLX (1:4) SD of HK was prepared using the solvent evaporation method. The morphology of the obtained HK–PLX (1:4) SD was different from that of free HK. The HK in the HK–PLX (1:4) SD existed in amorphous form and formed intermolecular hydrogen bonds with PLX.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/014 1075A1 Talbott (43) Pub
    US 2006O141075A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/014 1075A1 Talbott (43) Pub. Date: Jun. 29, 2006 (54) METHODS AND COMPOSITIONS FOR Publication Classification WEIGHT MANAGEMENT AND MOOD ENHANCEMENT (51) Int. Cl. A6IR 36/82 (2006.01) A6IR 36/752 (2006.01) (76) Inventor: Shawn M. Talbott, Draper, UT (US) A6II 3/522 (2006.01) A6II 3/56 (2006.01) Correspondence Address: A6IR 33/26 (2006.01) MACPHERSON KWOK CHEN & HEID LLP A 6LX 36/575 (2006.01) 1762 TECHNOLOGY DRIVE, SUITE 226 (52) U.S. Cl. ......................... 424/729; 424/736: 424/774; SAN JOSE, CA 95110 (US) 424/769; 514/263.31; 514/171; 424/646 (21) Appl. No.: 11/360,312 (57) ABSTRACT The present invention provides nutritional Supplement com (22) Filed: Feb. 23, 2006 positions and processes for treatment using nutritional Supplements that assist in weight management. One aspect Related U.S. Application Data of the invention comprises the inclusion in a single Supple ment constituent(s) that assist in reduction of a subjects (62) Division of application No. 10/895.253, filed on Jul. cortisol level, thermogenic constituent(s), and constituent(s) 20, 2004. that assist in stabilizing blood Sugar levels. Patent Application Publication Jun. 29, 2006 Sheet 1 of 4 US 2006/01.41075A1 Global Mood State (Profile of Mood States) 160 -8.6% 150 140 130 120 o Mood, Pre 110 Effect of a stress/cortisol-controlling dietary supplement on Global Mood States following 12 weeks of supplementation. P = placebo. S = Supplement. * = P <0.05 compared to Pre.
    [Show full text]
  • Herbal Insomnia Medications That Target Gabaergic Systems: a Review of the Psychopharmacological Evidence
    Send Orders for Reprints to [email protected] Current Neuropharmacology, 2014, 12, 000-000 1 Herbal Insomnia Medications that Target GABAergic Systems: A Review of the Psychopharmacological Evidence Yuan Shia, Jing-Wen Donga, Jiang-He Zhaob, Li-Na Tanga and Jian-Jun Zhanga,* aState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China; bDepartment of Pharmacology, School of Marine, Shandong University, Weihai, P.R. China Abstract: Insomnia is a common sleep disorder which is prevalent in women and the elderly. Current insomnia drugs mainly target the -aminobutyric acid (GABA) receptor, melatonin receptor, histamine receptor, orexin, and serotonin receptor. GABAA receptor modulators are ordinarily used to manage insomnia, but they are known to affect sleep maintenance, including residual effects, tolerance, and dependence. In an effort to discover new drugs that relieve insomnia symptoms while avoiding side effects, numerous studies focusing on the neurotransmitter GABA and herbal medicines have been conducted. Traditional herbal medicines, such as Piper methysticum and the seed of Zizyphus jujuba Mill var. spinosa, have been widely reported to improve sleep and other mental disorders. These herbal medicines have been applied for many years in folk medicine, and extracts of these medicines have been used to study their pharmacological actions and mechanisms. Although effective and relatively safe, natural plant products have some side effects, such as hepatotoxicity and skin reactions effects of Piper methysticum. In addition, there are insufficient evidences to certify the safety of most traditional herbal medicine. In this review, we provide an overview of the current state of knowledge regarding a variety of natural plant products that are commonly used to treat insomnia to facilitate future studies.
    [Show full text]
  • NRDC: Generally Recognized As Secret
    NRDC Report April 2014 Generally Recognized as Secret: Chemicals Added to Food in the United States Tom Neltner, J.D., Maricel Maffini, Ph.D. Natural Resources Defense Council In April 2014, the Natural Resources Defense Council (NRDC) released a report raising concerns about a loophole in the Food Additives Amendment of 1958 for substances designated by food manufacturers as “generally recognized as safe” (GRAS). The report identified 56 companies that appeared to market 275 chemicals for use in food based on undisclosed GRAS safety determinations. For each chemical we identified in this study, we did not find evidence that FDA had cleared them for use in food. The 1958 law exempted from the formal, extended FDA approval process common food ingredients like vinegar and vegetable oil whose use qualifies as GRAS. It may have appeared reasonable at the time, but that exemption has been stretched into a loophole that has swallowed the law. The exemption allows manufacturers to make safety determinations that the uses of their newest chemicals in food are safe without notifying the FDA. The agency’s attempts to limit these undisclosed GRAS determinations by asking industry to voluntarily inform the FDA about their chemicals are insufficient to ensure the safety of our food in today’s global marketplace with a complex food supply. Furthermore, no other developed country in the world has a system like GRAS to provide oversight of food ingredients. In Table 1 and 2 of the report, NRDC identified the 56 companies and the number of chemicals that each company appeared to market as GRAS without FDA clearance.
    [Show full text]
  • Preparation of Submicron Particles for Theranostic Applications: Imaging
    Preparation of submicron particles for theranostic applications : imaging and therapy Muhammad Iqbal To cite this version: Muhammad Iqbal. Preparation of submicron particles for theranostic applications : imaging and therapy. Other. Université Claude Bernard - Lyon I, 2015. English. NNT : 2015LYO10227. tel- 01290059 HAL Id: tel-01290059 https://tel.archives-ouvertes.fr/tel-01290059 Submitted on 17 Mar 2016 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. N°d’ordre: 227-2015 Année 2015 THESE Présentée devant L’UNIVERSITE CLAUDE BERNARD – Lyon 1 Pour l’obtention du Diplôme de DOCTORAT Spécialité Pharmacotechnie Par Muhammad IQBAL Soutenue publiquement le 13 Novembre 2015 “Préparation de particules submicroniques pour applications théranostiques: imagerie et thérapie” Jury : Salima Saidi Professeur Université d’Oran, Algeria Serge Stoll Professeur Université de Genève, Switzerland Stéphanie Briançon Professeur Université Claude Bernard Lyon 1, France Amane JADA CR1-HDR-CNRS Institut de Sciences Des Matériaux De Mulhouse Hatem Fessi Professeur Co-directeur de thèse (Université Lyon-1) Abdelhamid Elaissari DR-CNRS Directeur de thèse (LAGEP, Université Lyon-1) UNIVERSITE CLAUDE BERNARD - LYON 1 Président de l’Université M. François-Noël GILLY Vice-président du Conseil d’Administration M.
    [Show full text]
  • Therapeutic Applications of Compounds in the Magnolia Family
    Pharmacology & Therapeutics 130 (2011) 157–176 Contents lists available at ScienceDirect Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/pharmthera Associate Editor: I. Kimura Therapeutic applications of compounds in the Magnolia family Young-Jung Lee a, Yoot Mo Lee a,b, Chong-Kil Lee a, Jae Kyung Jung a, Sang Bae Han a, Jin Tae Hong a,⁎ a College of Pharmacy and Medical Research Center, Chungbuk National University, 12 Gaesin-dong, Heungduk-gu, Cheongju, Chungbuk 361-763, Republic of Korea b Reviewer & Scientificofficer, Bioequivalence Evaluation Division, Drug Evaluation Department Pharmaceutical Safety Breau, Korea Food & Drug Administration, Republic of Korea article info abstract Keywords: The bark and/or seed cones of the Magnolia tree have been used in traditional herbal medicines in Korea, Magnolia China and Japan. Bioactive ingredients such as magnolol, honokiol, 4-O-methylhonokiol and obovatol have Magnolol received great attention, judging by the large number of investigators who have studied their Obovatol pharmacological effects for the treatment of various diseases. Recently, many investigators reported the Honokiol anti-cancer, anti-stress, anti-anxiety, anti-depressant, anti-oxidant, anti-inflammatory and hepatoprotective 4-O-methylhonokiol effects as well as toxicities and pharmacokinetics data, however, the mechanisms underlying these Cancer Nerve pharmacological activities are not clear. The aim of this study was to review a variety of experimental and Alzheimer disease clinical reports and, describe the effectiveness, toxicities and pharmacokinetics, and possible mechanisms of Cardiovascular disease Magnolia and/or its constituents. Inflammatory disease © 2011 Elsevier Inc. All rights reserved. Contents 1. Introduction .............................................. 157 2. Components of Magnolia ........................................ 159 3. Therapeutic applications in cancer ...................................
    [Show full text]
  • Honokiol Inhibits Lung Tumorigenesis Through Inhibition of Mitochondrial Function
    Published OnlineFirst September 22, 2014; DOI: 10.1158/1940-6207.CAPR-14-0091 Cancer Prevention Research Article Research Honokiol Inhibits Lung Tumorigenesis through Inhibition of Mitochondrial Function Jing Pan1, Qi Zhang1, Qian Liu1, Steven M. Komas2, Balaraman Kalyanaraman2, Ronald A. Lubet3, Yian Wang1, and Ming You1 Abstract Honokiol is an important bioactive compound found in the bark of Magnolia tree. It is a non- adipogenic PPARg agonist and capable of inhibiting the growth of a variety of tumor types both in vitro and in xenograft models. However, to fully appreciate the potential chemopreventive activity of honokiol, a less artificial model system is required. To that end, this study examined the chemopreven- tive efficacy of honokiol in an initiation model of lung squamous cell carcinoma (SCC). This model system uses the carcinogen N-nitroso-trischloroethylurea (NTCU), which is applied topically, reliably triggering the development of SCC within 24 to 26 weeks. Administration of honokiol significantly reduced the percentage of bronchial that exhibit abnormal lung SCC histology from 24.4% bronchial in control to 11.0% bronchial in honokiol-treated group (P ¼ 0.01) while protecting normal bronchial histology (present in 20.5% of bronchial in control group and 38.5% of bronchial in honokiol-treated group. P ¼ 0.004). P63 staining at the SCC site confirmed the lung SCCs phenotype. In vitro studies revealed that honokiol inhibited lung SCC cells proliferation, arrested cells at the G1–S cell-cycle checkpoint, while also leading to increased apoptosis. Our study showed that interfering with mitochondrial respiration is a novel mechanism by which honokiol changed redox status in the mitochondria, triggered apoptosis, and finally leads to the inhibition of lung SCC.
    [Show full text]
  • 4-O-Methylhonokiol Protects Hacat Cells from TGF-Β1-Induced Cell Cycle Arrest by Regulating Canonical and Non-Canonical Pathways of TGF-Β Signaling
    Original Article Biomol Ther 25(4), 417-426 (2017) 4-O-Methylhonokiol Protects HaCaT Cells from TGF-β1-Induced Cell Cycle Arrest by Regulating Canonical and Non-Canonical Pathways of TGF-β Signaling Sang-Cheol Kim1,3 Jung-Il Kang1, Jin-Won Hyun1, Ji-Hoon Kang1, Young-Sang Koh1, Young-Heui Kim2, Ki-Ho Kim2, Ji-Hee Ko1, Eun-Sook Yoo1 and Hee-Kyoung Kang1,* 1Department of Medicine, Jeju National University School of Medicine, Jeju 63243, 2R&D Center, Bioland Ltd., Cheonan 31257, 3Freshwater Bioresources Utilization Division, Nakdonggang National Institute of Biological Resourecs, Sangju 37242, Republic of Korea Abstract 4-O-methylhonokiol, a neolignan compound from Magnolia Officinalis, has been reported to have various biological activities including hair growth promoting effect. However, although transforming growth factor-β (TGF-β) signal pathway has an essen- tial role in the regression induction of hair growth, the effect of 4-O-methylhonokiol on the TGF-β signal pathway has not yet been elucidated. We thus examined the effect of 4-O-methylhonokiol on TGF-β-induced canonical and noncanonical pathways in HaCaT human keratinocytes. When HaCaT cells were pretreated with 4-O-methylhonokiol, TGF-β1-induced G1/G0 phase arrest and TGF-β1-induced p21 expression were decreased. Moreover, 4-O-methylhonokiol inhibited nuclear translocation of Smad2/3, Smad4 and Sp1 in TGF-β1-induced canonical pathway. We observed that ERK phosphorylation by TGF-β1 was significantly at- tenuated by treatment with 4-O-methylhonokiol. 4-O-methylhonokiol inhibited TGF-β1-induced reactive oxygen species (ROS) production and reduced the increase of NADPH oxidase 4 (NOX4) mRNA level in TGF-β1-induced noncanonical pathway.
    [Show full text]
  • Honokiol Potentiates Apoptosis, Suppresses Osteoclastogenesis, and Inhibits Invasion Through Modulation of Nuclear Factor-KB Activation Pathway
    Honokiol Potentiates Apoptosis, Suppresses Osteoclastogenesis, and Inhibits Invasion through Modulation of Nuclear Factor-KB Activation Pathway Kwang Seok Ahn,1 Gautam Sethi,1 Shishir Shishodia,1 Bokyung Sung,1 Jack L. Arbiser,2 and Bharat B. Aggarwal1 1Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas and 2Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia Abstract results indicate that NF-KBandNF-KB-regulated Recent reports have indicated that honokiol can gene expression inhibited by honokiol enhances induce apoptosis, suppress tumor growth, and inhibit apoptosis and suppresses osteoclastogenesis and angiogenesis. In this report, we found that honokiol invasion. (Mol Cancer Res 2006;4(9):621–33) potentiated the apoptosis induced by tumor necrosis factor (TNF) and chemotherapeutic agents, Introduction suppressed TNF-induced tumor cell invasion, and More than 80% of the world population cannot afford inhibited RANKL-induced osteoclastogenesis, all of modern medicine and thus must rely on traditional medicine. which are known to require nuclear factor-KB(NF-KB) Although practiced for centuries, traditional medicine suffers activation. Honokiol suppressed NF-KB activation from the fact that both the chemical entity responsible for the induced by a variety of inflammatory stimuli, and activity and its molecular targets are not well defined. this suppression was not cell type specific. Further Nonetheless, as much as 70% of all drugs approved by the studies showed that honokiol blocked TNF-induced Food and Drug Administration for cancer between 1980 and phosphorylation, ubiquitination, and degradation 2000 have been from natural sources (1). Thus, identification of of IKBA through the inhibition of activation of IKBA the chemical entity of traditional medicine and its targets can kinase and of Akt.
    [Show full text]
  • Honokiol and Magnolol As Renewable Resources for the Synthesis of Polymers Towards Biomedical and Engineering Applications
    HONOKIOL AND MAGNOLOL AS RENEWABLE RESOURCES FOR THE SYNTHESIS OF POLYMERS TOWARDS BIOMEDICAL AND ENGINEERING APPLICATIONS A Dissertation by KEVIN T. WACKER Submitted to the Office of Graduate and Professional Studies of Texas A&M University in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY Chair of Committee, Karen L. Wooley Committee Members, Lei Fang Jaime C. Grunlan David C. Powers Head of Department, Simon W. North May 2018 Major Subject: Chemistry Copyright 2018 Kevin T. Wacker ABSTRACT This dissertation has focused on the design, synthesis, and characterization of novel polymers derived from the renewable resources honokiol and magnolol. These natural products – isolated from magnolia officinalis – are highly functional and, thus, amenable to a broad range of synthetic organic transformations. The transformations explored in this work have yielded diverse monomers and, subsequently, polymer types which have included polycarbonates, thermosets, and olefin-based polymers that were studied for potential engineering or biomedical materials. A guiding theme in the development of polymers from honokiol and magnolol has been to control and vary the final polymer properties through the monomer design and polymerization chemistry. This work has used scalable syntheses, well-known chemistries, and, as the first examples of polymers synthesized from these natural products, it has laid the foundation to further explore material applications and new polymers based on honokiol and magnolol. Poly(honokiol carbonate) (PHC) was synthesized in one step from honokiol using step-growth polycondensation techniques. Synthetic conditions were screened to yield polymers of varying molecular weight and the resulting polymers were studied in their thermomechanical and biological properties.
    [Show full text]
  • Honokiol and Magnolol As Multifunctional Antioxidative Molecules for Dermatologic Disorders
    Molecules 2010, 15, 6452-6465; doi:10.3390/molecules15096452 OPEN ACCESS molecules ISSN 1420-3049 www.mdpi.com/journal/molecules Review Honokiol and Magnolol as Multifunctional Antioxidative Molecules for Dermatologic Disorders Jui-Lung Shen 1,2,3,#, Kee-Ming Man 2,4,5,#, Po-Hsun Huang 6, Wen-Chi Chen 4, Der-Cherng Chen 4, Ya-Wen Cheng 1, Po-Len Liu 7,*, Ming-Chih Chou 1,*, and Yung-Hsiang Chen 4,* 1 Institute of Medicine, Chung Shan Medical University, Taichung; Taiwan; E-Mails: [email protected] (J.L.S.); [email protected] (Y.W.C.) 2 Department of Anesthesiology, Tungs’ Taichung MetroHarbor Hospital, Taichung; Taiwan; E-Mail: [email protected] (K.M.M.) 3 Department of Dermatology, Taichung Veterans General Hospital, Taichung; Taiwan 4 Graduate Institute of Integrated Medicine, College of Chinese Medicine, Graduate Institute of Clinical Medical Science, Department of Urology, Department of Neurosurgery, China Medical University and Hospital, Taichung; Taiwan; E-Mails: [email protected] (W.C.C.); [email protected] (D.C.C.); [email protected] (Y.H.C.) 5 Graduate Institute of Geriatric Medicine, Anhui Medical University, Hefei; China 6 Division of Cardiology, Taipei Veterans General Hospital, Institute of Clinical Medicine, Cardiovascular Research Center, National Yang-Ming University, Taipei; Taiwan; E-Mail: [email protected] 7 Department of Respiratory Therapy, College of Medicine, Kaohsiung Medical University, Kaohsiung; Taiwan; E-Mail: [email protected] # Jui-Lung Shen and Kee-Ming Man contributed equally to this study. * Author to whom correspondence should be addressed; E-mail: [email protected] (P.L.); [email protected] (M.C.); [email protected] (Y.C.); Tel.: +886-4-22053366-3512; Fax: +886-4-2203-7690.
    [Show full text]
  • Phytochemicals Having Neuroprotective Properties from Dietary Sources and Medicinal Herbs
    PHCOG J REVIEW ARTICLE Phytochemicals Having Neuroprotective Properties from Dietary Sources and Medicinal Herbs G. Phani Kumar*, K.R. Anilakumar and S. Naveen Applied Nutrition Division, Defence Food Research Laboratory (DRDO), Ministry of Defence, India ABSTRACT Many neuropsychiatric and neurodegenerative disorders, such as Alzheimer's disease, anxiety, cerebrovascular impairment, depression, seizures, Parkinson's disease, etc. are predominantly appearing in the current era due to the stress full lifestyle. Treatment of these disorders with prolonged administration of synthetic drugs will lead to severe side effects. In the recent years, scientists have focused the attention of research towards phytochemicals to cure neurological disorders. Nootropic herb refers to the medicinal role of various plants/parts for their neuroprotective properties by the active phytochemicals including alkaloids, steroids, terpenoids, saponins, phenolics, flavonoids, etc. Phytocompounds from medicinal plants play a major part in maintaining the brain's chemical balance by acting upon the function of receptors for the major inhibitory neurotransmitters. Medicinal plants viz. Valeriana officinalis, Nardostachys jatamansi, Withania somnifera, Bacopa monniera, Ginkgo biloba and Panax ginseng have been used widely in a variety of traditional systems of therapy because of their adaptogenic, psychotropic and neuroprotective properties. This review highlights the importance of phytochemicals on neuroprotective function and other related disorders, in particular
    [Show full text]